Back to search

Article

Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002

2021-11-29

Abstract excerpt

<title>Abstract</title> <p> Background and objective: Osimertinib as first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor (EGFR) mutations remains controversial. Sequential EGFR-tyrosine kinase inhibitor (TKI) might be superior to the first line osimertinib in patients at risk of developing acquired T790M mutations. <h4>Methods:</h4> We enrolled consecutive...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d2e9198c-685b-52e2-8c55-a281cfab0b8e
DOI
10.21203/rs.3.rs-1079146/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002DOI 10.21203/rs.3.rs-1079146/v1
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.Semantic proximity
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLCSemantic proximity
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulationsSemantic proximity
Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.Semantic proximity
Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.Semantic proximity
The Role of De Novo T790M Mutation in The Origin of T790M Resistance Clone and in The Clinical Outcomes For Advanced EGFR-Mutant NSCLC Patients Receiving EGFR-TKIsSemantic proximity
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.Semantic proximity
Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients.Semantic proximity
[Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant Gene Mutation in Advanced Lung Adenocarcinoma].Semantic proximity
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.Semantic proximity
[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].Semantic proximity
[Patient with Three EGFR Mutations - Gradual Development of Resistance to Previous Targeted Treatment].Semantic proximity
Select a neighboring publication to make it the new centre.